Nalaganje...

Definition and management of ruxolitinib treatment failure in myelofibrosis

Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF). Several other JAK inhibitors are in development with some currently undergoing phase-3 clinical trial testing....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Cancer J
Main Authors: Pardanani, A, Tefferi, A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2014
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315890/
https://ncbi.nlm.nih.gov/pubmed/25501025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.84
Oznake: Označite
Brez oznak, prvi označite!